Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Select amongst our broad range of solutions and experience.
Vendor consolidation with a top 10 pharma company
Read more about how we consolidated over 340 site management resources, from 70 vendors, across 30 countries resulting in a 91% reduction in client burden.
Data analytics enabled FSP solutions
In a multi-vendor FSP model for clinical monitoring, the client required the capability to aggregate and analyse data internally across all FSP providers.
Promoting growth and reducing turnover through rapid and efficient resource allocation
Due to unprecedented resourcing needs prompted by the COVID-19 pandemic, our large pharma partner required rapid and efficient resource allocation in an FSP model to reduce turnover and promote growth.
Virtual development model
A venture-backed biopharmaceutical company focused on therapies for rare diseases needed to accelerate late-stage development and commercialization. ICON provided technical and commercial assessments, collaborating closely to simplify the development program and develop ePROs and a novel biomarker approach for the rare disease asset.
Cardiac imaging and monitoring support for PAH trial
ICON provided a large pharma sponsor with consistent, accurate ECG and ECHO modality imaging, contributing to a breakthrough pulmonary arterial hypertension treatment.
Long-term benefits of FSP partnerships in biometrics
The sponsor sought out ICON’s data management resources for their support in several international and complex programs using our FSP model across several therapeutic areas: oncology, neurology, infectious disease, endocrinology, and nephrology.
Creating an industry-leading clinical operations risk management function
Discover how ICON's cross-functional collaboration led to to creation of an industry-leading clinical risk management platform.
Out-performing ambitions with strategic capacity management
Explore how we built a dedicated global infrastructure of functional hubs, reducing the cost per FTE by over 20% and resulting in 20% productivity savings.
Creating a pool of high-quality CRA talent
An accelerated training program for Early Development Oncology CRAs was required to significantly increase the cohort of CRA talent across 7 countries globally.
Strategic site management
A top ten pharmaceutical company needed clinical site support in an FSP model as it changed its pipeline to focus on complex oncology studies. The introduction of a Site Engagement Liaison delivered significant efficiencies and reduced risk.
Large scale transformation delivers lasting results in clinical monitoring
A top five biopharma company makes the radical move to transform the delivery of all clinical site management activities to an FSP model.
Technical evaluations for asset investment
ICON evaluated the probability of achieving regulatory approval of a stem cell therapy for the treatment of an acute immunological condition in adult and paediatric patients.
Let's collaborate
Discover how ICON's expertise transforms clinical trials.